Your Search Returned 78 tagged news reports
DiPaola, MD, director of Rutgers Cancer Institute of New Jersey has been selected to receive the Melvyn H. Motolinsky Research Foundation Distinguished Service Award in recognition of his accomplishments and leadership in the field of oncology. Dr.
Board of Directors has appointed Kristiina Vuori , M.D., Ph.D., President and Interim CEO of Sanford-Burnham Medical Research Institute, to the Company's Board. The Institute is a non-profit research organization that is dedicated to discovering the
HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer
Between Florida's size and its senior population, cancer treatment is needed here more than in most other states. Yet Florida has only one facility Tampa's Moffitt Cancer Center with the prestigious National Cancer Institute designation. According to
Jude Children's Research Hospital Renewed as NCI-Designated Comprehensive Cancer Center St...Jude Children's Research Hospital's designation as a Comprehensive Cancer Center has been renewed by the National Cancer Institute (NCI), earning the highest
The previous structure of the NCI's national clinical trials program, which brought together nine adult Cooperative Groups, was deemed to be inefficient...Roswell Park faculty leaders: Ellis Levine, MD, Professor of Oncology in the Department of
West Yorkshire's NCI has joined the Aquarium stable of top insurance brands, as it becomes the latest to take advantage of Aquarium's intimate understanding of the technology needs of the global pet insurance sector. (Photo: http://photos.
National Institute of Health's National Cancer Institute (NCI) Vaccine Branch to study the efficacy and mechanism of action of the company's in situ chemovaccination products using in vivo models of cancer...According to NCI chief of the Vaccine
Chemical sleuthing by scientists at The Scripps Research Institute has put ownership of a new cancer drug in doubt, opening the door for a San Diego biotech company. The experimental drug, patented by Oncoceutics is about to enter clinical trials.
I uncovered unsubstantiated claims and implausible mechanisms that persisted after peer review in another blog post about the respected, high journal-impact-factor (JIF = 18.03) Journal of Clinical Oncology. We obviously cannot depend on peer